In the previous paper, 1) we reported the synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. These derivatives were found as new antiproliferative agents through random screening using our laboratory's chemical library. One of them, 3-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propene (2), showed significant antitumor activity against several tumor models by both intraperitoneal injection and oral administration. Furthermore, 2 was free from the cross-resistance to some currently used antitumor agents such as vincristine (VCR) and adriamycin (ADM). These pyrazole derivatives, however, tended to cause undesirable effects, e.g., muscle relaxation and decrease of body temperature without body weight loss, because these compounds had previously been prepared as tranquilizers or antihypertensive agents. To overcome these problems, we have been seeking derivatives of 1 that might furthermore increase the antitumor activity while decreasing the side effects. As a first step in the structural modification of this scaffold, we focused on the phenylpiperazine moiety, namely, the introduction of some substituents on the phenyl ring and replacement of the phenylpiperazinyl group with some piperidinyl groups. We describe here the synthesis and structure-activity relationships (SARs) with regard to in vitro cytotoxic activity and in vivo antitumor activity of these pyrazole derivatives.
In the previous paper, 1) we reported the synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. These derivatives were found as new antiproliferative agents through random screening using our laboratory's chemical library. One of them, 3-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propene (2), showed significant antitumor activity against several tumor models by both intraperitoneal injection and oral administration. Furthermore, 2 was free from the cross-resistance to some currently used antitumor agents such as vincristine (VCR) and adriamycin (ADM). These pyrazole derivatives, however, tended to cause undesirable effects, e.g., muscle relaxation and decrease of body temperature without body weight loss, because these compounds had previously been prepared as tranquilizers or antihypertensive agents. To overcome these problems, we have been seeking derivatives of 1 that might furthermore increase the antitumor activity while decreasing the side effects. As a first step in the structural modification of this scaffold, we focused on the phenylpiperazine moiety, namely, the introduction of some substituents on the phenyl ring and replacement of the phenylpiperazinyl group with some piperidinyl groups. We describe here the synthesis and structure-activity relationships (SARs) with regard to in vitro cytotoxic activity and in vivo antitumor activity of these pyrazole derivatives.
Chemistry
The synthesis of the derivatives bearing a substituted phenylpiperazine moiety was carried out via the route shown in Chart 1. The new substituted piperazines 4a-d were prepared from aniline derivatives 3a-d and bis(2-chloroethyl)amine hydrochloride. Mannich reaction of 4-acetyl-5-methyl-1-pyrimidinylpyrazole (5) 1) with modified piperazines 4a-d or 4e-i 2) gave 6a-i, respectively. 1-Propanone derivatives 6j-l were prepared according to the reported procedure.
3) Compounds 6a-l were reduced with sodium borohydride to give the corresponding alcohols, which were dehydrated by p-toluenesulfonic acid (p-TsOH) to afford 1-trans-propene derivatives 7a-l. Catalytic hydrogenation of 6i over Pd/C with acetic anhydride gave the 3-acetylaminophenyl derivative 8. Compound 9 was obtained from 8 by the same procedure as described for 7a-l from 6a-l. Carbamoylphenyl derivative 10 was prepared from 7c by hydrolysis of the cyano group with hydrochloride.
We also developed a new, efficient synthetic method to construct this scaffold by employing reductive amination instead of Mannich reaction, because Mannich reaction of hydroxyphenylpiperazine 15 with 5 did not progress (Chart 2). Bromination of 5 with Br 2 and treatment with cesium acetate (CsOAc) gave 11. Compound 11 was hydrolyzed with aqueous NaOH to give the a-hydroxyketone, followed by reduction with sodium borohydride, and then oxidative cleavage of the 1,2-diol with sodium periodate to give the aldehyde 12. According to the Mukaiyama protocol, 4) the carbon-carbon bond formation of 12 with allyl bromide was performed using metallic tin, followed by protection of the secondary alcohol with triethylsilyl chloride to give 13. Oxidation of 13 with osmium tetraoxide (OsO 4 ), followed by oxidative cleavage of the 1,2-diol with sodium periodate gave the aldehyde 14. The above method demonstrated the synthesis of the key intermediate 14 in 40% overall yield through 9 steps from 5. The reductive amination of 15 with 14 by treatment with NaBH 3 CN in acetic acid (AcOH)/EtOH gave the corresponding adduct, followed by deprotection and simultaneous dehydration with p-TsOH to afford the 1-trans-propene derivative 16.
Furthermore, some derivatives 21a-l with other variations as modifications of the piperazine or phenyl group were synthesized via the route shown in Chart 3. Compound 19a was prepared via a palladium(II)-catalyzed aromatic amination reaction 5) with 1-bromo-3,5-difluorobenzene (17a) and the unprotected 1,4-diazepane. 1-Bromo-3,5-dichlorobenzene (17b) was converted to 18b through a palladium-catalyzed cross-coupling reaction 6 ) with 2-cyclopentene-1-one in the presence of the phosphine ligand. Compound 18b was treated with hydroxylamine to afford the imine, followed by the rearrangement with polyphosphoric acid and reduction with lithium aluminum hydride (LAH) to construct the 4-phenylpiperidine skeleton 19b. Mannich reaction of 5 with 19a-f gave 20a-f. Compounds 20g-l were prepared according to the reported procedure.
3) 1-trans-Propene derivatives 21a-l were obtained from 20a-l by the same procedure as described in Chart 1.
Modification of the piperazine moiety was carried out via the routes shown in Charts 4 and 5. Aminoethylation of 22 with 2-oxazolidinone as an aziridine equivalent 7) afforded the desired N-phenylethylenediamine (23). 2-Piperazinone 24 was prepared from 23 in two steps (2-chloropropanoyl chloride, Et 3 N, CH 2 Cl 2 , then K 2 CO 3 , tert-BuOH), and the following reduction of the amide with LAH afforded 26a. Compound 26b was prepared via a palladium(II)-catalyzed aromatic amination reaction with the unprotected 2-methylpiperazine. 5) Compounds 27a and 27b were obtained from 26a and 26b, respectively, by the sequence of reactions described in Chart 2, because Mannich reaction with 5 did not progress (Chart 4).
The synthetic route to 31, which was not prepared from 29 by either Mannich reaction with 5 or reductive amination with 14, is shown in Chart 5. The N-phenylethylenediamine (23) was protected with benzyl chloroformate (ZCl), then treated with 2-bromoacethyl bromide followed by construction of the piperazinone with K 2 CO 3 to afford the protected 2-piperazinone 28. Deprotection of the Z group of 28 by hy-drogenation over Pd/C provided 29. The aldehyde 14 was reduced with NaBH 4 to give the corresponding primary alcohol, which was tosylated to afford the deprotected compound 30. Alkylation of 29 with 30 by treatment with K 2 CO 3 in MeCN gave the corresponding adduct, followed by dehydration with p-TsOH to afford the 1-trans-propene derivative 31.
Biological Activity and Discussion
The in vitro cytotoxic activity of these compounds was measured by using the human lung cancer cell lines PC-6 and PC-12, and the concentrations producing a 50% growth inhibitory effect (GI 50 ) are listed in Table 1 . Compounds 1, 2, and 5-fluorouracil (5-FU) were used as reference compounds, because 1 and 2 are orally available and the administration route is the same as that of 5-FU. Among a series of phenylpiperazinyl derivatives, 7a, e, f, j, and l having a fluorine or chlorine atom at the 3 or 5 position of benzene showed the highest in vitro cytotoxic activity, while the corresponding compounds 7b with a bromine atom at the 3 position and 7d with fluorine atoms at other positions of benzene showed moderate or weak activity. The activity of the corresponding compounds 7c, g-i bearing CN, Me, CF 3 , and NO 2 at the same position of the phenyl ring was moderate or weak. The hydroxy derivative 16 increased the activity compared to that of the non-substituted compound 1. The activity of the 3-methylphenyl compound 7g and the 3-trifluoromethylphenyl compound 7h was the same as that of the non-substituted phenylpiperazinyl derivative 1. Introduction of a bulky group to the 3 position of the phenyl ring caused a decrease of cytotoxic activity (9, 10). Strong cytotoxic activity was observed when the phenyl ring possessed a halogen atom at the 3 position. The order of in vitro potency was halogen atomϾhydroxy groupϾalkyl group. In the series of compounds 21a-l in Chart 3, only 21i bearing the tetrahydropyridinyl group showed almost the same activity as the non-substituted phenylpiperazine 1 against PC-6. The other compounds showed very weak or no activity. Introduction of a methyl group to the piperazine caused a decrease of cytotoxic activity (27a, b), and the piperazinone derivative 31 was not active. The phenylpiperazine moiety in this scaffold was considered to be essential for cytotoxic activity.
Compounds 7a, e, f, j, k, and l, which showed strong cytotoxic activity in vitro, were evaluated in the in vivo assay by employing murine fibrosarcoma Meth A as a solid tumor model. 5-FU was used as the reference compound. As shown in Table 2 , compounds 7a, e, j-l showed significantly potent antitumor activity by intraperitoneal injection compared to that of 5-FU. Among them, compounds 7a and 7e did not cause muscle relaxation or decrease of body temperature though these side effects were observed in prototypes 1 and 2 at the level of each maximum tolerated dose (MTD) in spite of same antitumor activity. Introduction of fluorine or chlorine atom at the 3 and 5 positions of benzene caused a de- Fig. 2 . Furthermore, compounds 7a and 7e were tested in the in vivo assay against murine P388 leukemia by intraperitoneal injection or oral administration. As shown in Table 3 , the antitumor activity of 7a and 7e by oral administration was the same as that of 2 and superior to that of 5-FU, although the effect of 7e was moderate when administered intraperitoneally. The optimal dose of 7e was about 10 times higher than that of 7a, even though these compounds exhibited almost the same cytotoxic activity in vitro. Therefore, the oral absorption rate of these two compounds in rats was evaluated using the intestinal loop method. 6) As a result, compound 7a displayed quite a high absorption rate of 87.2%, while that of 7e was 6.2%. It is interesting to note that only difference between a fluoride atom and chloride atom on the phenyl ring dramatically affected the oral absorbability.
Compounds 7a and 7e were selected for further evaluation against several multi-drug resistant (MDR) cell lines, PC-6/VCR and PC-6/ADM. These two cell lines have been reported to overexpress P-glycoprotein. 7) As shown in Table 4 , VCR and ADM showed high cross resistance rates of 400 against PC-6/VCR and 22 against PC-6/ADM, respectively. Compounds 7a and 7e did not show cross-resistance as indicated by their equal rates of 0.9 against PC-6/VCR and 1.3 against PC-6/ADM.
In conclusion, the study on structural modifications of the phenylpiperazine moiety in this scaffold 1 has resulted in the 456 Vol. 50, No. 4 discovery of 3,5-difluorophenyl and 3,5-dichlorophenyl compounds, 7a and 7e, that displayed potent antitumor activity in mice without causing a decrease of body temperature, compared with that caused by 2, on both intraperitoneal injection and oral administration. Furthermore, although the leading compound 2 in this scaffold caused muscle relaxation and crouching at MTD in mice, these visible symptoms were not observed for compound 7a. Mechanism of action for the cytotoxic activity of this scaffold was reported to be inhibition of tubulin polymerization. 8) Further work with 7a to investigate the inhibitory activity and the binding site on tubulin will be described elsewhere.
Experimental
Melting points were determined on a Yanaco MP-500D apparatus and are uncorrected. Infrared (IR) spectra were recorded on a JEOL JIR-5300 or Horiba FT-720 spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-EX400 (400 MHz) instrument, and the chemical shifts are given in d values. Mass spectra (MS) were recorded on a JEOL JMS-HX110 or a JMS-AX505W mass spectrometer. Elemental analyses were performed with a Perkin-Elmer Series II CHNS/O 2400 instrument. Column chromatography was performed with silica gel 60 F 254 (70-230 mesh) (Merck). Sodium sulfate was employed as a drying agent.
1-(3,5-Difluorophenyl)piperazine Hydrochloride (4a) A mixture of 3,5-difluoroaniline (3a) (10 g, 77 mmol) and bis(2-chloroethyl)amine hydrochloride (13.7 g, 77 mmol) in n-BuOH (120 ml) was refluxed for 48 h. Anhydrous sodium carbonate (10.6 g, 77 mmol) was added to the mixture. After being stirred for 24 h, the reaction mixture was cooled, and the precipitate obtained was filtered. The precipitate was suspended with water and extracted with CHCl 3 . The organic phase was washed with water, dried, and evaporated in vacuo. Et 2 O and 1 N HCl/EtOH (2.5 ml) were added to the residue, and the precipitate obtained was filtered to give 4a (12.6 g) as a white powder. Compounds 3b-d were treated in the same manner as described above to give 4b-d, respectively. 4a: Yield 74%, a white powder. 1) (1.0 g, 5.0 mmol) in EtOH (85 ml), and the mixture was heated to reflux for 4 d. The mixture was diluted with CHCl 3 , successively washed with saturated aqueous NaHCO 3 and brine, and then dried. Evaporation of the solvents afforded the crude mixture, which was chromatographed on a silica gel column (CHCl 3 /MeOHϭ50/1) to give 6a (129 mg, 6%) as a yellow caramel. Compounds 4b-i were treated in the same manner as described above to give 6b-i, respectively. The physical data for these compounds and yields are shown in Table 5 .
3-[4-(3,5-Difluorophenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-1H-pyrazolyl]-1-trans-propene Hydrochloride (7a)
Sodium borohydride (50 mg, 1.3 mmol) was added in small portions to a solution of 6a (103 mg, 0.25 mmol) in anhydrous EtOH (10 ml) and THF (10 ml) at 0°C, and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with a solution of 1 N HCl/EtOH. The mixture was diluted with CHCl 3 , successively washed with saturated aqueous NaHCO 3 and brine, and dried. Evaporation of the solvents afforded the corresponding secondary alcohol. Next, p-TsOH · H 2 O (68 mg, 0.38 mmol) was added to a solution of the above product in anhydrous 1,4-dioxane (10 ml) and THF (10 ml), and the mixture was heated to reflux for 40 min. The reaction mixture was diluted with CHCl 3 , successively washed with saturated aqueous NaHCO 3 and brine, and dried. After removal of the solvents, the crude mixture was chromatographed on a silica gel column (CHCl 3 / MeOHϭ50/1) to afford the propene. An appropriate volume of a solution of 1 N HCl/EtOH was added to a solution of the propene in a small amount of EtOH, and the solvent was removed. The residue was recrystallized from EtOH to give 7a (39 mg, 35%) as a white powder. Compounds 6b-l were treated in the same manner as described above to give 7b-l, respectively. The physical data for these compounds and yields are shown in Table 6 .
3-[4-(3-Acetylamino)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-1H-pyrazolyl]-1-propanone (8)
Compound 6i (404 mg, 1.0 mmol) and acetic anhydride (113 ml) were dissolved in AcOH (22 ml) and hydrogenated over 10% Pd/C (110 mg) for 24 h at room temperature. The reaction mixture was filtered through a Celite pad, and the filtrate was evaporated to afford the crude mixture, which was chromatographed on a silica gel column (CHCl 3 / MeOHϭ100/3) to give 8 (277 mg, 63%) as a yellow caramel. The physical data for 8 are shown in Table 5 .
3-[4-(3-Acetylamino)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-1H-pyrazolyl]-1-trans-propene Hydrochloride (9)
Synthesis of 9 was performed as described for the synthesis of 7a. Compound 9 was obtained from 8 in 53% yield as a white powder. The physical data for 9 are shown in Table 6 .
3-[4-(3-Carbamoylphenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-1H-pyrazolyl]-1-trans-propene Hydrochloride (10)
Compound 7c (88 mg, 0.2 mmol) was dissolved in conc. HCl (0.5 ml), and the mixture was stirred for 62 h at room temperature. The reaction mixture was diluted with ice-water, alkalized with NaHCO 3 , and extracted with CHCl 3 . The organic layer was washed with brine and dried. After removal of the solvent, the crude residue was chromatographed on a silica gel column (CHCl 3 / MeOHϭ100/3) to afford the propene. An appropriate volume of a solution of 1 N HCl/EtOH was added to a solution of the propene in a small amount of EtOH, and the solvent was removed. The residue was recrystallized from EtOH to give 10 (50 mg, 54%) as a white powder. The physical data for 10 are shown in Table 6 .
2-[5-Methyl-1-(2-pyrimidinyl)-4-1H
-pyrazolyl]-2-oxoethyl Acetate (11) Bromine (0.5 ml) was added to a solution of 5 (2.0 g, 9.86 mmol) in AcOH (50 ml), and the mixture was stirred at 70°C for 1.5 h. The reaction mixture was diluted with AcOEt, washed with saturated aqueous NaHCO 3 and brine, and dried. Evaporation of the solvents afforded the crude mixture, which was recrystallized from EtOH to give the bromoethanone (2.8 g, quantitative yield) as colorless needles: Sodium borohydride (0.3 mg) was added to a solution of the primary alcohol (0.81 g, 3.69 mmol) in EtOH (20 ml) and tetrahydrofuran (THF, 10 ml) at 0°C, and the mixture was stirred at the same temperature for 20 min. The reaction mixture was quenched with a solution of 1 N HCl/EtOH, and the solvents were removed to afford the diol. Next, sodium periodate (4.0 g) was added to a solution of the above product in THF (15 ml) and water (3.0 ml), and the mixture was stirred at room temperature for 1 h. The mixture was diluted with AcOEt, washed with brine, and dried. After removal of the solvents, the residue was chromatographed on a silica gel column (CHCl 3 /AcOEtϭ2/1) to give 12 (0.52 g, 75%) as a white caramel: Imidazole (100 mg, 1.46 mmol) and chlorotetraethylsilane (2.45 ml, 1.46 mmol) were added successively to a solution of the alcohol (112 mg, 0.49 mmol) in anhydrous DMF (3.0 ml) at 0°C, and the mixture was stirred for 12 h. Water (10 ml) was added to the mixture, and the whole was extracted with AcOEt. The organic layer was washed with brine and dried. After removal of the solvents, the residue was chromatographed on a silica gel column (CHCl 3 /MeOHϭ99/1) to afford 13 (170 mg, quantitative yield) as a pale yellow oil: and a catalytic amount of osmium tetraoxide were added to a solution of 13 (1.59 g, 4.61 mmol) in THF (20 ml) and water (5 ml), and the mixture was stirred at room temperature for 24 h. A suspension of sodium periodate (4.93 g, 23.1 mmol) in water (20 ml) was added to the above mixture at room temperature, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with CHCl 3 , washed with brine, and dried. After removal of the solvents, the residue was chromatographed on a silica gel column (CHCl 3 /MeOHϭ99/1) to give 14 (0.91 g, 57%) as a pale yellow oil: .85 mmol) in MeOH (170 ml), and the mixture was stirred at room temperature for 2.5 h. The reaction mixture was diluted with CHCl 3 , washed with saturated aqueous NaHCO 3 and brine, and dried. Evaporation of the solvents afforded the corresponding adduct. Next, a solution of 1 N HCl/EtOH (10 ml) was added to a solution of the above product in EtOH (10 ml), and the mixture was stirred at room temperature for 17 h. After removal of the solvents, the crude mixture was dissolved in THF (15 ml) and 1,4-dioxane (15 ml). pTsOH · H 2 O (275 mg, 1.45 mmol) was added to a solution of the crude mixture in anhydrous 1,4-dioxane (5 ml) and THF (5 ml), and the mixture was heated to reflux for 2 h. The reaction mixture was diluted with CHCl 3 , successively washed with saturated aqueous NaHCO 3 and brine, and dried. After removal of the solvents, the crude mixture was chromatographed on a silica gel column (CHCl 3 /MeOHϭ50/3) to afford the propene. An appropriate volume of a solution of 1 N HCl/EtOH was added to a solution of the propene in a small amount of EtOH, and the solvent was removed. The residue was recrystallized from EtOH to give 16 (113 mg, 25%) as a white powder. The physical data for 16 are shown in Table 6 . 3 g ) and hydroxylamine hydrochloride (0.68 g, 9.9 mmol) were added to a solution of 18b (1.13 g, 5.0 mmol) in MeOH (20 ml) and water (10 ml), and the mixture was heated to reflux for 2 h. The reaction mixture was diluted with CHCl 3 , washed with water and brine, and dried. Removal of the solvents afforded the corresponding oxime. To this residue was added polyphosphoric acid (10 g), and the mixture was stirred at 80°C for 2 h. The reaction mixture was diluted with ice-water, neutralized with NaHCO 3 , and extracted with CHCl 3 . The organic layer was washed with brine and dried. After removal of the solvents, the crude mixture was chromatographed on a silica gel column (CHCl 3 /AcOEtϭ1/1) to afford the mixture of 4-(3,5-dichlorophenyl)-2-piperidinone and 5-(3,5-dichlorophenyl)-2-piperidinone (800 mg, 66%) as a red caramel. The ratio of 4-(3,5-dichlorophenyl)-2-piperidinone and the isomer was about 1 : 1 based on the NMR spectrum. This mixture was used in the next reaction without further purification: FAB-MS m/z 244 (M ϩ ϩH). A solution of the mixture of the above 2-piperidinones (800 mg, 3.3 mmol) in THF (20 ml) was added to a suspension of LAH (370 mg, 9.7 mmol) in THF (40 ml) at 0°C, and the mixture was heated to reflux for 5 h. The reaction mixture was carefully quenched with AcOEt, and the whole was filtered through a Celite pad. The filtrate was concentrated to afford the mixture of 19b and 3-(3,5-dichlorophenyl)piperidine (800 mg, quantitative yield as the mixture) as a pale red oil. This mixture was used in the next Mannich reaction without further purification: FAB-MS m/z 228 (M ϩ Pd/C (250 mg) for 10 min at room temperature. The reaction mixture was filtered through a Celite pad, and the filtrate was evaporated to afford the crude mixture, which was chromatographed on a silica gel column (CHCl 3 /MeOHϭ30/1) to give 29 (326 mg, 67%) as a yellow oil:
1 H-NMR (CDCl 3 ) d: 7.0-6.8 (2H, m), 6.8-6.6 (2H, m), 3.70 (2H, s), 3.68 (2H, t, Jϭ5 Hz), 3.23 (2H, t, Jϭ5 Hz).
3-Hydroxy-3-[5-methyl-1-(2-pyrimidinyl)-4-1H-pyrazolyl]propyl-4-methyl-benzenesulfonate (30) Sodium borohydride (38 mg, 1.0 mmol) was added to a solution of 14 (328 mg, 0.95 mmol) in MeOH (4.0 ml) at 0°C, and the mixture was stirred at the same temperature for 1 h. A solution of 1 N HCl/EtOH (1.0 ml) and water (20 ml) was successively added to the reaction mixture, and the whole was extracted with CHCl 3 . The organic layer was dried and then evaporated in vacuo to afford the primary alcohol (296 mg). Next, p-toluenesulfonyl chloride (361 mg, 1.84 mmol) was added to a solution of the above product in pyridine (3.0 ml) at 0°C, and the mixture was stirred at the same temperature for 24 h. The mixture was diluted with CHCl 3 , washed with brine, and dried. After removal of the solvents, the residue was chromatographed on a silica gel column (CHCl 3 /MeOHϭ95/5) to give the tosylate, which was kept in a refrigerator overnight to afford 30 (350 mg, 74%) as a pale yellow oil: (33 mg, 0.15 mmol) and K 2 CO 3 (11 mg) were added to a solution of 30 (30 mg, 0.077 mmol) in CH 3 CN (1 ml) and THF (10 ml), and the mixture was stirred at 60°C for 30 min. The reaction mixture was diluted with CHCl 3 , washed with brine, and then dried. Evaporation of the solvents afforded the corresponding adduct. Next, p-TsOH · H 2 O (50 mg, 0.263 mmol) was added to a solution of the above product in anhydrous 1,4-dioxane (3 ml) and THF (3 ml), and the mixture was heated to reflux for 40 min. The reaction mixture was diluted with CHCl 3 , successively washed with saturated aqueous NaHCO 3 and brine, and dried. After removal of the solvents, the crude mixture was chromatographed on a silica gel column (CHCl 3 /MeOHϭ98/2) to afford the propene. An appropriate volume of a solution of 1 N HCl/EtOH was added to a solution of the propene in a small amount of EtOH, and the solvent was removed. The residue was recrystallized from EtOH to give 31 (14 mg, 51%) as a white powder. The physical data and yields are shown in Table 6 .
In Vitro Cytotoxicity To examine the direct growth-inhibitory effects of the test compounds against PC-6 and PC-12 human non-small cell lung cancer cell lines and resistant cell lines (PC-6/VCR and PC-6/ADM), the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed, and the concentration giving a growth inhibition of 50% (GI 50 ) was calculated according to a published procedure.
9)
Evaluation of Therapeutic Effect in Vivo P388 cells (1ϫ10 6 ) were inoculated i.p. into CDF1 mice (6 mice per group) on day 0. Compounds were suspended in BTC salt solution (0.9% benzyl alcohol, 0.4% Tween 80, 0.5% carboxymethyl cellulose, 0.9% NaCl) and administered i.p. or p.o. on days 1 and 5, or days 1-5 consecutively. The increase in life span (ILS) was calculated by the following formula: ILS (%)ϭ[(median survival time of treated group)/(median survival time of control group)Ϫ1]ϫ100. Meth A murine fibrosarcoma cells (1ϫ10 6 ) were implanted into the right flank of BALB/c mice (day 0). Compounds were administered p.o. on days 7-11 consecutively. Tumor weights were measured on day 17. The tumor growth-inhibition rate (IR) was calculated by the formula: IR (%)ϭ(1ϪTWt/TWc)ϫ100 (%), where TWt represents the mean of tumor weight of a treated group, and TWc represents that of the control group. To evaluate the intensity of the side effects of compounds, the rate of body weight loss (BWL) was utilized as a parameter of toxicity. The maximum value of BWL was designated as BWLmax, and a BWLmax of less than zero indicates no body weight loss.
